Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNTI Senti Biosciences, Inc.

Pre-Mkt 04-22 04:58:59 EDT

1.10

-0.04

-3.51%

盘前1.17

+0.07+6.34%

04:21 EDT

High1.17	Low1.07	Vol297.58K
Open1.17	D1 Closing1.14	Amplitude8.77%
Mkt Cap34.26M	Tradable Cap16.04M	Total Shares31.14M
T/O331.33K	T/O Rate2.04%	Tradable Shares14.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SNTI","market":"US","secType":"STK","nameCN":"Senti Biosciences, Inc.","latestPrice":1.1,"timestamp":1776801600000,"preClose":1.14,"halted":0,"volume":297577,"hourTrading":{"tag":"盘前","latestPrice":1.1697,"preClose":1.1,"latestTime":"04:21 EDT","volume":2702,"amount":3100.1840128,"timestamp":1776846060319,"change":0.0697,"changeRate":0.063364,"amplitude":0.063364},"delay":0,"changeRate":-0.03508771929824545,"floatShares":14577400,"shares":31144500,"eps":-2.732594,"marketStatus":"Pre-Mkt","change":-0.04,"latestTime":"04-22 04:58:59 EDT","open":1.17,"high":1.17,"low":1.07,"amount":331334.730034,"amplitude":0.087719,"askPrice":1.2,"askSize":2000,"bidPrice":1.01,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.732594,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776864600000},"marketStatusCode":1,"adr":0,"listingDate":1622001600000,"exchange":"NASDAQ","adjPreClose":1.1,"preHourTrading":{"tag":"盘前","latestPrice":1.1697,"preClose":1.1,"latestTime":"04:21 EDT","volume":2702,"amount":3100.1840128,"timestamp":1776846060319,"change":0.0697,"changeRate":0.063364,"amplitude":0.063364},"postHourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.1,"latestTime":"19:50 EDT","volume":16975,"amount":18558.6441,"timestamp":1776815417511,"change":-0.02,"changeRate":-0.018182,"amplitude":0.036364},"volumeRatio":0.8405709579019595},"requestUrl":"/m/hq/s/SNTI","defaultTab":"news","newsList":[{"id":"2627455375","title":"Senti Bio CEO Timothy Lu to present logic-gated NK cell therapy at AACR meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627455375","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627455375?lang=en_us&edition=fundamental","pubTime":"2026-04-13 21:03","pubTimestamp":1776085439,"startTime":"0","endTime":"0","summary":"Senti Biosciences CEO Timothy Lu will present at AACR Annual Meeting 2026 in San Diego on April 17, 2026.Talk will cover logic-gated engineered NK cell therapy SENTI-202, including clinical trial results in relapsed or refractory acute myeloid leukemia.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL5QLxR6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","BK4112","BK4539","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","SNTI","LU0314104364.USD","BK4139","LU2095319765.USD","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624820542","title":"BRIEF-Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624820542","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624820542?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:31","pubTimestamp":1775079101,"startTime":"0","endTime":"0","summary":"BRIEF-Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC FilingApril 1  - Senti Biosciences, Inc SNTI.O:SENTI BIOSCIENCES INC - ANNOUNCES HOLDING COMPANY REORGANIZATION EFFECTIVE BY APRIL 16, 2026 - SEC FILINGSENTI BIOSCIENCES, INC: UPON EFFECTIVENESS OF HOLDING COMPANY REORGANIZATION, SENTI BIOSCIENCES HOLDINGS WOULD BECOME SUCCESSOR ISSUER TO COSource text: [ID:n0001628280-26-022824]Further company coverage: SNTI.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0X8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNTI","BK4539"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2624541678","title":"Senti Biosciences plans tax-free holding company reorganization by April 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2624541678","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624541678?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:34","pubTimestamp":1775075673,"startTime":"0","endTime":"0","summary":"Senti Biosciences announced plans to implement a holding-company reorganization, targeted to take effect by April 16, 2026.Transaction structure calls for a tax-free merger into a newly formed merger subsidiary under newly created parent Senti Biosciences Holdings.Existing common shares will automatically convert on a 1-for-1 basis into shares of Senti Biosciences Holdings with equivalent rights.Nasdaq trading is expected to continue under ticker SNTI on an uninterrupted basis, with a new CUSIP.Reorganization is not expected to change directors, management, assets, or operations on a consolidated basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDLMSdBk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515011","title":"Senti Bio study in Cell Systems advances NOT-gated CAR design for T and NK therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515011?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:45","pubTimestamp":1775047521,"startTime":"0","endTime":"0","summary":"Senti Biosciences announced publication in Cell Systems on April 1, 2026, outlining a logic-gated CAR design framework intended to improve safety and precision of engineered cell therapies.Preclinical findings showed NOT-gated CAR designs could help immune cells eliminate tumor cells while sparing healthy tissue, supporting a broader therapeutic window where clean tumor-specific targets are limited.Research also indicated optimized designs may reduce cell exhaustion and sustain anti-cancer activity with repeat exposure, which could improve durability of responses.Company filed a patent application covering aspects of technology described in study, positioning Gene Circuit platform for wider use across CAR T and CAR NK modalities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL5QDq0S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SNTI","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","BK4588","SG9999014021.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4585","BK4139","IE00BKPKM429.USD","BK4539","IE00BN0W2V16.EUR","LU0314104364.USD","LU2210150020.SGD","LU2210149790.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317550","title":"Senti Biosciences Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317550","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317550?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:07","pubTimestamp":1774872420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNTI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 08:07 ET (12:07 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311875","title":"Chardan Cuts Price Target on Senti Biosciences to $11 From $13, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311875","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623311875?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:00","pubTimestamp":1774868418,"startTime":"0","endTime":"0","summary":"Chardan Cuts Price Target on Senti Biosciences to $11 From $13, Keeps Buy Rating","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNTI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622295498","title":"Senti Biosciences Q4 EPS $(0.53) Misses $(0.48) Estimate, Sales $22.000K Miss $666.667K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622295498","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622295498?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:19","pubTimestamp":1774613967,"startTime":"0","endTime":"0","summary":"Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.48) by 11.11 percent. This is a 20.9 percent increase over losses of $(0.67) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51505086/senti-biosciences-q4-eps-0-53-misses-0-48-estimate-sales-22-000k-miss-666-667k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNTI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622298128","title":"Senti Biosciences Q4 revenue misses analyst estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2622298128","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622298128?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:11","pubTimestamp":1774613474,"startTime":"0","endTime":"0","summary":"Senti Biosciences Q4 revenue misses analyst estimatesOverviewUS biotech firm's Q4 revenue missed analyst expectationsAdjusted EPS for Q4 was a lossCompany reported positive preliminary clinical data f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL1N40F0DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622157826","title":"BRIEF-Senti Biosciences Q4 Net Income USD -14.467 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622157826","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622157826?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:00","pubTimestamp":1774612846,"startTime":"0","endTime":"0","summary":"BRIEF-Senti Biosciences Q4 Net Income USD -14.467 Million\n\n\nMar 27 (Reuters) - Senti Biosciences Q4 revenue USD 22 thousand.\n\nQ4 EPS USD -0.53\nQ4 operating expenses USD 18.658 million\nQ4 operating income USD -18.636 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nPLX314FBF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622826184","title":"Senti Biosciences Q4 EPS USD -0.53","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826184","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826184?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:00","pubTimestamp":1774612801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nPLX314FBF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622826183","title":"Senti Biosciences Q4 Revenue USD 22 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826183","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826183?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:00","pubTimestamp":1774612801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nPLX314FBF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNTI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622149826","title":"Press Release: Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622149826","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622149826?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:00","pubTimestamp":1774612800,"startTime":"0","endTime":"0","summary":"\"2025 was a year of important progress for Senti as we continued to advance our mission of developing next-generation cell and gene therapies powered by our synthetic biology platform. Over the past year, we have strengthened the clinical and translational foundation of our pipeline, with SENTI-202 as the lead program generating positive clinical data, while continuing to refine and expand the capabilities of our Gene Circuit platform. We remain focused on disciplined execution, advancing our key programs toward critical development milestones and positioning Senti to deliver smarter, more selective medicines for patients with serious diseases. I am proud of our team's commitment and believe the progress we made in 2025 positions us well for the opportunities ahead,\" commented Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences.-- Reported updated positive preliminary clinical data from the ongoing. , demonstrating encouraging response rates, durability, and a. -- Received Reg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNTI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621706455","title":"Senti Biosciences to present SENTI-202 Phase 1 data at 11th Annual Innate Killer Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706455","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706455?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:05","pubTimestamp":1774271107,"startTime":"0","endTime":"0","summary":"Senti Bio will present clinical and translational data on its SENTI-202 program at the 11th Annual Innate Killer Conference on March 24-25, 2026, in San Diego, California.Rochelle Emery is scheduled to give a clinical data presentation on Phase I results from the SENTI-202-101 study.Brian Garrison is scheduled to lead a workshop on biomarker discovery and translational tools for NK cell therapy development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief on March 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL5rh7BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620949974","title":"Senti Biosciences Inc  expected to post a loss of 41 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620949974","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620949974?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:17","pubTimestamp":1773692230,"startTime":"0","endTime":"0","summary":"Senti Biosciences Inc  expected to post a loss of41cents a share - Earnings Preview Senti Biosciences Inc SNTI.OQ SNTI.O is expected to  show a rise in quarterly revenue when it reports  results on Ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL8N404285:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNTI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616325497","title":"Senti Biosciences CEO Timothy Lu to Present at Leerink Partners Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2616325497","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616325497?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:06","pubTimestamp":1772546760,"startTime":"0","endTime":"0","summary":"Senti Biosciences CEO Timothy Lu to Present at Leerink Partners Global Healthcare Conference               Senti Biosciences, Inc. will present at the Leerink Partners 2026 Global Healthcare Conferenc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL1nPf8w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU0314104364.USD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014005.SGD","BK4585","BK4139","SG9999014013.SGD","SNTI","LU2095319765.USD","BK4207","IE00BGHQF748.EUR","NDAQ","BK4539","SG9999014039.USD","SG9999014021.USD","BK4588","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4112","MNSH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613717404","title":"Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717404","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613717404?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:15","pubTimestamp":1771942540,"startTime":"0","endTime":"0","summary":"data=S_Eelhm-6r8Uxqy3crHpe0FIyHrfKjFY4dalpcGWx4UGhgnPVJbubxcbPbCVp_8f8BXu63fCVRhw-wFe_xjW6g==), and live video is available here: https://www.globenewswire.com/Tracker?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL9BSlkf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B64PRP62.GBP","LU0314104364.USD","SNTI","IE00B3QW5Z07.USD","BK4588","LU2210149790.SGD","NDAQ","BK4139","SG9999014005.SGD","SG9999014039.USD","BK4585","SG9999014013.SGD","BK4539","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612267613","title":"Senti Biosciences Joins Cell & Gene Live Virtual Event on Emerging Cell Therapy Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2612267613","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612267613?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:50","pubTimestamp":1771595409,"startTime":"0","endTime":"0","summary":"Senti Biosciences participated in the Cell & Gene Live virtual event on Feb. 19, 2026, joining industry leaders to discuss emerging technologies aimed at improving the design, development, and translation of cell therapies. The company highlighted how its Gene Circuit platform is intended to enhance precision, control, and functionality in engineered cell therapies, including its logic-gated SENTI-202 program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL5vzFQP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014021.USD","BK0046","BK4588","BK0188","LU0314104364.USD","BK0042","SNTI","NDAQ","LU2210149790.SGD","BK4539","BK0216","IE00B3QW5Z07.USD","BK4585","BK4112","IE00BGHQF748.EUR","BK4139","SG9999014039.USD","600645","SG9999014005.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK0239","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610953226","title":"BRIEF-Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Senti-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2610953226","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610953226?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:03","pubTimestamp":1770818606,"startTime":"0","endTime":"0","summary":"BRIEF-Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Senti-202 Feb 11 (Reuters) - Senti Biosciences Inc SNTI.O:SENTI BIOSCIENCES COMPLETES ENROLLMENT IN PHASE 1 CLINICAL TRIAL OF ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA4PGH1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610958992","title":"Senti Biosciences Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2610958992","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610958992?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:35","pubTimestamp":1770816909,"startTime":"0","endTime":"0","summary":"Senti Biosciences Inc. announced the completion of enrollment in its Phase 1 clinical trial of SENTI-202, a CD33/FLT3-targeting Logic Gated CAR NK cell therapy for patients with relapsed or refractory acute myeloid leukemia . The company recently presented positive clinical data from this study at the American Society of Hematology  Annual Meeting, demonstrating deep, MRD-negative, durable complete remissions and a favorable safety profile in a heavily pretreated patient population. SENTI-202 has received Regenerative Medicine Advanced Therapy  designation, which may expedite its development and review process. Senti Biosciences plans to engage with the U.S. Food and Drug Administration in the first half of 2026 to discuss the potential pivotal registration program for SENTI-202 in R/R AML and possible expansion to newly diagnosed and pediatric AML indications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLbzllmp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4585","SG9999014013.SGD","LU0314104364.USD","LU2210149790.SGD","BK4112","SNTI","SG9999014021.USD","IE00BGHQF748.EUR","BK4539","SG9999014005.SGD","NDAQ","LU2095319765.USD","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610586619","title":"Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of Senti-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R Aml)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610586619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610586619?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:35","pubTimestamp":1770816900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA4PGH1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","SNTI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sentibio.com","stockEarnings":[{"period":"1week","weight":0.185},{"period":"1month","weight":0.1957},{"period":"3month","weight":0.0185},{"period":"6month","weight":-0.45},{"period":"1year","weight":-0.7229},{"period":"ytd","weight":0.0577}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0856},{"period":"3month","weight":0.0273},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.3701},{"period":"ytd","weight":0.0325}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.037903},{"month":2,"riseRate":0.2,"avgChangeRate":-0.117173},{"month":3,"riseRate":0.2,"avgChangeRate":-0.07377},{"month":4,"riseRate":0.4,"avgChangeRate":0.026195},{"month":5,"riseRate":0.25,"avgChangeRate":-0.078726},{"month":6,"riseRate":0,"avgChangeRate":-0.301397},{"month":7,"riseRate":0.4,"avgChangeRate":0.120052},{"month":8,"riseRate":0.4,"avgChangeRate":-0.119944},{"month":9,"riseRate":0.4,"avgChangeRate":-0.088688},{"month":10,"riseRate":0.6,"avgChangeRate":0.032318},{"month":11,"riseRate":0.4,"avgChangeRate":0.12033},{"month":12,"riseRate":0.4,"avgChangeRate":0.047383}],"exchange":"NASDAQ","name":"Senti Biosciences, Inc.","nameEN":"Senti Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Senti Biosciences, Inc.(SNTI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Senti Biosciences, Inc.,SNTI,Senti Biosciences, Inc.股票,Senti Biosciences, Inc.股票老虎,Senti Biosciences, Inc.股票老虎国际,Senti Biosciences, Inc.行情,Senti Biosciences, Inc.股票行情,Senti Biosciences, Inc.股价,Senti Biosciences, Inc.股市,Senti Biosciences, Inc.股票价格,Senti Biosciences, Inc.股票交易,Senti Biosciences, Inc.股票购买,Senti Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Senti Biosciences, Inc.(SNTI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction